Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study

PURPOSE: As a third-generation EGFR TKI has been taken orally, Osimertinib effectively inhibits mutant EGFR, including T790M EGFR resistance mutations. Here, we examined real-world efficacy and tolerability of Osimertinib among Chinese patients with advanced EGFR T790M-mutant NSCLC. PATIENTS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Da, Shan, Dongfeng, Dai, Chengcheng, Li, Jie, Wang, Zifan, Huang, Ziyi, Peng, Rui, Zhao, Peng, Ma, Xuezhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926038/
https://www.ncbi.nlm.nih.gov/pubmed/33679141
http://dx.doi.org/10.2147/CMAR.S287466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926038/
https://www.ncbi.nlm.nih.gov/pubmed/33679141
http://dx.doi.org/10.2147/CMAR.S287466

Ejemplares similares